Medical treatment of brain tumours, particularly glioma, with an emphasis on novel drug evaluation for glioblastoma
18 F-Fluorodeoxyglucose positron-emission tomography for the investigation of malignancy in patients with suspected paraneoplastic neurologic syndromes and negative or indeterminate conventional imaging: a retrospective analysis of the Ontario PET...
Curr Oncol. 2019 Aug;26(4):e458-e465
Neurosurgery. 2019 Jun 19;:
Cognitive rehabilitation for executive dysfunction in brain tumor patients: a pilot randomized controlled trial.
J Neurooncol. 2019 May;142(3):565-575
Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue.
J Clin Oncol. 2019 Jan 04;:JCO1800474
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
Oncologist. 2018 Sep 28;:
PLoS One. 2018;13(8):e0202860
Significance of treatment response when managing patients with primary central nervous system lymphoma.
Leuk Lymphoma. 2018 Jul 03;:1-9
Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide and bevacizumab or placebo.
Neuro Oncol. 2018 Apr 20;:
Validation of post-operative residual contrast enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.
Neuro Oncol. 2018 Apr 05;:
Neuro Oncol. 2018 Mar 28;:
Clinician Investigator, Princess Margaret Cancer Centre
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Associate Professor, Department of Medicine, University of Toronto
Medical Director, Gerry and Nancy Pencer Brain Tumour Centre
Kirchmann Family Chair in Neurooncology Research, Princess Margaret Hospital